Australia's most trusted
source of pharma news
Posted 30 June 2025 AM
AstraZeneca has pulled its long-standing breast cancer treatment Faslodex from the Australian market as three companies, including the UK pharma giant itself, inch closer to commercialising their next generation medicines.
Faslodex, which is administered via an intramuscular injection was the only Selective Estrogen Receptor Degrader (SERD) available up until around 2020 when generic versions of the drug started to trickle onto the ARTG before being listed on the PBS from March 2021 onwards.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.